Alzheimer's Disease
Many of us have been touched by Alzheimer’s disease in one way or another. The burden of this disease is growing, but organizations like the Alliance for Aging Research are working to help those impacted to manage the disease, and to support research that would slow and even stop Alzheimer’s.Search our recent publications and resources listed below to learn more about this disease, and to find tools that can help you care for a loved one (while taking care of yourself, too). If you are interested in joining the fight to eliminate Alzheimer’s, visit www.act-ad.org.
Visit the Alzheimer's Disease Corner to learn more about Alzheimer's and the resources offered by the Alliance.
Related Publications
-
Alliance in the News, Feature ArticleFollowing Katz at FDA
February 11, 2013 | Steve Usdin, Washington Editor
Related topics: Alzheimer's Disease Drug Development PolicyOn February 11, 2013, Steve Usdin, Washington Editor of BioCentury, published an article in BioCentury The Bernstein Report on Business focused on the future of the FDA’s Division of Neurology Products following the expected retirement later this year of the current Division Director, Russell Katz, M.D. Representatives from the biopharmaceutical industry and the patient advocacy community were interviewed for this article, including Daniel Perry, President & CEO of the Alliance for Aging research and Chair of the ACT-AD Coalition. Mr. Perry highlighted ACT-AD’s positive relationship with Dr. Katz and expressed hope that Dr. Katz’s successor will approach the review of therapies for Alzheimer’s disease with similar openness and flexibility.
To read the BioCentury article, click here.
-
Get Mad ColumnHelping Stop a Devastating Disease: The ACT-AD Coalition Continues its Important Work in Alzheimer's
Winter 2013
Related topics: Access to Breakthroughs Alzheimer's Disease Drug Development Health PolicyAlzheimer's disease is a slow, dehumanizing, and fatal disease that strikes 1 in 8 people over the age of 65. While it's typically thought of as a disease that affects memory, it goes well beyond memory loss and eventually leads to death. -
Press ReleaseStatement on FDA Draft Guidance for Alzheimer’s Drug Development
February 7, 2013 | Alliance for Aging Research
Related topics: Alzheimer's Disease Drug Development PolicyStatement on FDA Draft Guidance for Alzheimer’s Drug Development
Washington, DC (February 7, 2013) - Today Daniel Perry, President and CEO of the Alliance for Aging Research and Chairman of the Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD)coalition released the following statement in response to guidance from the U.S. Food and Drug Administration (FDA) on the development of drugs for Alzheimer’s Disease.
